Adele Presents Poster on Tau Antibody Therapy at AAIC

Adele, a company developing treatments for Alzheimer's disease, announced on the 6th that it presented a poster on its tau antibody therapeutic candidate ADEL-Y01, currently under development as an Alzheimer's treatment, at the Alzheimer's Association International Conference (AAIC 2024) held in Philadelphia, USA, from the 28th of last month to the 1st of this month (local time).

원본보기 아이콘

AAIC is the world's largest dementia conference, where researchers and industry professionals from around the globe gather annually to share research achievements on Alzheimer's disease treatment. It is a major conference covering a wide range of approaches related to Alzheimer's and dementia, from basic research to preclinical trials, clinical trials, regulatory approval, policy, and dementia caregiving. Leading scientists, clinicians, and major pharmaceutical companies worldwide attend.

At this year's AAIC, Adele presented the design of the Phase 1 clinical trial of ADEL-Y01, co-developed with Oscotec, in the United States, as well as research results comparing the inhibitory effects on tau protein aggregation and seeding between tau antibodies already developed or under development by global pharmaceutical companies.

Tau protein, along with amyloid-beta protein, is presumed to be one of the proteins that cause Alzheimer's disease in the brain. Under normal conditions, tau stabilizes the structure of nerve cells, but in disease states, tau proteins detach and seed and aggregate, disrupting nerve cell function. This process continues to spread to other nerve cells, eventually causing cognitive impairment symptoms.

Regarding this, Adele explained that it has confirmed in several preclinical models that targeting the acetylated lysine 280 site in the MTBR domain, which is expected to be pathogenic, can have excellent efficacy in suppressing neurotoxicity and cognitive impairment.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.